Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Osimertinib
Related studies linked through entity extraction aliases.
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer
- Status
- UNKNOWN
- Phase
- PHASE1
Osimertinib Study in Indian Patients
- Status
- COMPLETED
- Phase
- PHASE4
Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS)
- Status
- COMPLETED
- Phase
- PHASE2
First-line Treatment With Osimertinib in EGFR-mutated Non-small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Osimertinib in Subjects With Advanced Non-Small Cell Lung Cancer EGFR-T790M Mutation-positive
- Status
- COMPLETED
- Phase
- N/A
T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC
- Status
- TERMINATED
- Phase
- PHASE2
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma
- Status
- COMPLETED
- Phase
- PHASE2
Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Osimertinib In EGFR Mutant Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC
- Status
- COMPLETED
- Phase
- PHASE2
Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC
- Status
- COMPLETED
- Phase
- PHASE1